［1］ HAN BF,ZHENG RS,ZENG HM,et al.Cancer incidence and mortality in China,2022［J］.Journal of the National Cancer Center,2024,4(1):47-53.
［2］ LLOVET JM,KELLEY RK,VILLANUEVA A,et al.Hepatocellular carcinoma［J］.Nature Reviews,2021,7(1):6.
［3］ ZHANG TQ,GENG ZJ,ZUO MX,et al.Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET):a phase Ⅱ study［J］.Signal Transduction and Targeted Therapy,2023,8(1):413.
［4］ PAWARODE A,VORAVUD N,SRIURANPONG V,et al.Natural history of untreated primary hepatocellular carcinoma:a retrospective study of 157 patients［J］.American Journal of Clinical Oncology,1998,21(4):386-391.
［5］ SHI J,LAI ECH,LI N,et al.A new classification for hepatocellular carcinoma with portal vein tumor thrombus［J］.Journal of Hepato-Biliary-Pancreatic Sciences,2011,18(1):74-80.
［6］ KUDO M,KITANO M,SAKURAI T,et al.General rules for the clinical and pathological study of primary liver cancer,nationwide follow-up survey and clinical practice guidelines:The outstanding achievements of the liver cancer study group of Japan［J］.Digestive Diseases,2015,33(6):765-770.
［7］ SUN JX,GUO RP,BI XY,et al.Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 edition)［J］.Liver Cancer,2022,11(4):315-328.
［8］ SITZMANN JV,ABRAMS R.Improved survival for hepatocellular cancer with combination surgery and multimodality treatment［J］.Annals of Surgery,1993,217(2):149.
［9］ OURA K,MORISHITA A,TANI J,et al.Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma:A review［J］.International Journal of Molecular Sciences,2021,22(11):5801.
［10］ KIM J,CHENG JCH,NAM TK,et al.Efficacy of liver-directed combined radiotherapy in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis［J］.Cancers,2023,15(12):3164.
［11］ WEI XB,JIANG YB,ZHANG XP,et al.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study［J］.Journal of Clinical Oncology,2019,37(24):2141-2151.
［12］ LI N,FENG S,XUE J,et al.Hepatocellular carcinoma with main portal vein tumor thrombus:a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy［J］.HPB,2016,18(6):549-556.
［13］ HAMAOKA M,KOBAYASHI T,KURODA S,et al.Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy:A retrospective cohort study［J］.International Journal of Surgery,2017,44:223-228.
［14］ KOSAKA Y,KIMURA T,KAWAOKA T,et al.Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein［J］.Liver Cancer,2021,10(2):151-160.
［15］ MARTELLETTI C,RICOTTI A,GESUALDO M,et al.Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis:A propensity score and Bayesian analysis［J］.Journal of Digestive Diseases,2021,22(8):496-502.
［16］ EDELINE J,CROUZET L,CAMPILLO-GIMENEZ B,et al.Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis［J］.European Journal of Nuclear Medicine and Molecular Imaging,2016,43(4):635-643.
［17］ GARIN E,ROLLAND Y,EDELINE J,et al.Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis［J］.Journal of Nuclear Medicine,2015,56(3):339-346.
［18］ GARIN E,LENOIR L,EDELINE J,et al.Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients:a new personalized promising concept［J］.European Journal of Nuclear Medicine and Molecular Imaging,2013,40(7):1057-1068.
［19］ MEERUN MA,ALLIMANT C,RIVIERE B,et al.Large,multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry:safety,pathological results and outcomes after surgery［J］.Hepatobiliary Surgery and Nutrition,2023,12(3):351-365.
［20］ SERENARI M,CAPPELLI A,CUCCHETTI A,et al.Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis:A pilot study［J］.Liver Transplantation,2021,27(12):1758-1766.
［21］ LI S,GUO JH,LU J,et al.125I irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis:A meta-analysis［J］.Cancer Radiothé Rapie,2021,25(4):340-349.
［22］ DING YX,WANG SS,QIU ZK,et al.The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma［J］.Frontiers in Immunology,2023,14:1284937.
［23］ LEE BH,LEE DS,CHO CW,et al.Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients with Child-Pugh class A［J］.World Journal of Surgical Oncology,2019,17(1):143.
［24］ ONISHI H,NOUSO K,NAKAMURA S,et al.Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion［J］.Hepatology International,2015,9(1):105-112.
［25］ CHONG JU,CHOI GH,HAN DH,et al.Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus［J］.Annals of Surgical Oncology,2018,25(11):3308-3315.
［26］ HAN S,LEE HW,PARK JY,et al.Appraisal of long-term outcomes of liver-directed concurrent chemoradiotherapy for hepatocellular carcinoma with major portal vein invasion［J］.Journal of Hepatocellular Carcinoma,2020,7:403-412.
［27］ TSAI HM,HAN MZ,LIN YJ,et al.Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis［J］.Cancer Immunology,Immunotherapy,2021,70(7):1929-1937.
［28］ ZHU XD,HUANG C,SHEN YH,et al.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations［J］.Liver Cancer,2021,10(4):320-329.
［29］ HUANG C,ZHU XD,SHEN YH,et al.Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma:a retrospective analysis［J］.Biomarker Research,2021,9(1):19.
［30］ FINN RS,IKEDA M,ZHU AX,et al.Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.Journal of Clinical Oncology,2020,38(26):2960-2970.
［31］ HE MK,LI QJ,ZOU RH,et al.Sorafenib plus hepatic arterial infusion of oxaliplatin,fluorouracil,and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion:A randomized clinical trial［J］.JAMA Oncology,2019,5(7):953-960.
［32］ XU YJ,LAI ZC,HE MK,et al.Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma［J］.Technology in Cancer Research & Treatment,2021,20:15330338211063848.
［33］ LIU BJ,GAO S,ZHU X,et al.Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma［J］.Immunotherapy,2021,13(17):1395-1405.
［34］ YUAN YC,HE W,YANG ZW,et al.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus:a propensity score matching study［J］.International Journal of Surgery,2023,109(5):1222-1230.
［35］ CHANG Y,JEONG SW,YOUNG JJ,et al.Recent updates of transarterial chemoembolization in hepatocellular carcinoma［J］.International Journal of Molecular Sciences,2020,21(21):8165.
［36］ LYU WF,LIU KC,LU D,et al.Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis［J］.Cancer Management and Research,2018,10:4719-4726.
［37］ CHUNG GE,LEE JH,KIM HY,et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival［J］.Radiology,2011,258(2):627-634.
［38］ NIU ZJ,MA YL,KANG P,et al.Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:using a new classification［J］.Medical Oncology,2012,29(4):2992-2997.
［39］ LUO J,GUO RP,LAI ECH,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study［J］.Annals of Surgical Oncology,2011,18(2):413-420.
［40］ LI XL,GUO WX,HONG XD,et al.Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus:A propensity score analysis［J］.Hepatology Research,2016,46(11):1088-1098.
［41］ LI XL,GUO WX,GUO L,et al.Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus?A propensity score matching study［J］.Oncotarget,2018,9(36):24537-24547.
［42］ YOON SM,RYOO BY,LEE SJ,et al.Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion:A randomized clinical trial［J］.JAMA Oncology,2018,4(5):661-669.
［43］ SHI J,LAI ECH,LI N,et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］.Annals of Surgical Oncology,2010,17(8):2073-2080.
［44］ WANG L,FENG JK,LU CD,et al.Salvage surgery for initially unresectable HCC with PVTT converted by locoregional treatment plus tyrosine kinase inhibitor and anti-PD-1 antibody［J］.The Oncologist,2024,29(8):e1041-e1050.